Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17188609 | 1.00 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2NPSR1AOC3 | |
| SCHEMBL13058137 | 1.00 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2NPSR1AOC3 | |
| SCHEMBL9618279 | 0.80 | TSHR (0.43) | MEN1KMT2AMAOBALDH1A1MAPK1 | |
| SCHEMBL4631460 | 0.79 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2NPSR1HDAC1 | |
| SCHEMBL4631463 | 0.79 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2NPSR1HDAC1 | |
| SCHEMBL10630432 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2ASMN1; SMN2NPSR1TRPA1 | |
| SCHEMBL10880294 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2ASMN1; SMN2NPSR1TRPA1 | |
| SCHEMBL10630435 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2ASMN1; SMN2NPSR1TRPA1 | |
| SCHEMBL6568111 | 0.77 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2NPSR1TRPA1 | |
| SCHEMBL11032398 | 0.77 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2NPSR1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| EP-2844637-B1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9815782-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-9815782-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | disclosed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | disclosed |
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | AOC3, HAO1, VAPA | MEN1 4163/4885KMT2A 4025/4885SMN1; SMN2 1418/4885 |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | AOC3, HAO1, VAPA | MEN1 4163/4885KMT2A 4025/4885SMN1; SMN2 1418/4885 |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | AOC3, HAO1, VAPA | MEN1 4163/4885KMT2A 4025/4885SMN1; SMN2 1418/4885 |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | MEN1 3253/4885KMT2A 3980/4885SMN1; SMN2 1608/4885 |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | HAO1, VAPA, AOC3 | MEN1 4287/4885KMT2A 3489/4885SMN1; SMN2 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.